Shilpa Medicare

859.45
-29.85
(-3.36%)
Market Cap
8,404.64 Cr
EPS
8.04
PE Ratio
96.75
Dividend Yield
0.11 %
Industry
Healthcare
52 Week High
1,000.00
52 Week Low
555.00
PB Ratio
3.65
Debt to Equity
0.48
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+50.00 %
+50.00 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Shilpa Medicare's Shilpa Pharma Lifesciences Unit-1 has successfully completed a GMP inspection by ANVISA (Brazilian Health Regulatory Agency). The audit concluded with no critical or major observations, indicating a positive outcome for the company's manufacturing practices.
positive
Shilpa Pharma Lifesciences: Clears Brazilian GMP Inspection with Minor Observations3 days ago
Shilpa Pharma Lifesciences Limited, Unit-1, a wholly-owned subsidiary of Shilpa Medicare Limited, successfully completed a Good Manufacturing Practice (GMP) inspection by Brazil's ANVISA from June 30 to July 4, 2025. The audit concluded with no critical or major observations, only a few procedural points. The company will submit a Corrective and Preventive Action (CAPA) plan within the given timeframe.
positive
Shilpa Medicare's Shilpa Pharma Lifesciences Unit-1 has successfully passed a Good Manufacturing Practice (GMP) inspection conducted by ANVISA (Brazilian Health Regulatory Agency) with no major issues identified.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,672.50
#1 4,01,288.77
35.18
#1 54,729.00
12.06
#1 10,980
-18.99
48.33
6,938.00
1,84,182.10
83.40
9,360.00
0.89
2,117
23.05
68.54
1,488.30
1,20,211.16
23.71
28,409.50
7.12
5,291
30.28
54.26
3,322.40
1,12,445.11
59.20
11,539.40
11.59
1,911
10.91
62.08
1,283.80
1,07,142.24
#1 19.71
33,741.20
12.36
5,725
21.14
54.13
2,431.70
1,00,363.25
50.14
12,207.40
19.57
1,925
-10.91
59.65
983.20
98,932.93
21.52
22,573.80
13.82
3,977
-0.19
69.99
1,922.10
87,781.44
27.52
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,160.00
72,587.62
51.77
6,409.15
10.80
1,417
27.83
64.97
1,147.70
66,658.60
19.91
31,378.10
17.55
3,366
-0.50
63.70
Forecast
Actual
Growth Rate
Revenue Growth
8.65 %
Net Income Growth
-203.23 %
Cash Flow Change
-24.78 %
ROE
-201.71 %
ROCE
534.38 %
EBITDA Margin (Avg.)
94.38 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Fixed Assets
316
393
492
534
558
650
1,111
1,342
1,368
1,385
2,193
Current Assets
328
354
730
672
545
624
903
887
770
877
986
Capital Work in Progress
222
92
141
210
429
666
541
506
655
719
463
Investments
65
94
253
140
2
11
21
34
43
40
348
Other Assets
302
352
587
615
621
662
959
993
838
950
0
Total Liabilities
905
931
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
Current Liabilities
189
222
237
266
253
411
604
612
784
693
674
Non Current Liabilities
154
67
251
154
167
257
561
453
345
600
273
Total Equity
561
642
984
1,080
1,190
1,322
1,468
1,811
1,774
1,800
2,372
Reserve & Surplus
539
632
979
1,077
1,189
1,321
1,471
1,814
1,775
1,800
2,363
Share Capital
8
8
8
8
8
8
8
9
9
9
10

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
9
3
93
-26
-40
10
79
-98
-7
11
Investing Activities
-196
-106
-257
-10
-196
-290
-404
-286
-232
-171
Operating Activities
69
129
38
45
147
124
47
105
180
135
Financing Activities
136
-20
313
-61
10
176
436
83
46
47

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Nov 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Apr 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
53.25 %
53.25 %
53.25 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
50.01 %
44.39 %
44.39 %
44.33 %
44.23 %
44.23 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
8.60 %
8.52 %
0.00 %
0.00 %
9.08 %
9.58 %
9.90 %
10.97 %
DIIs
2.95 %
2.05 %
2.29 %
2.15 %
2.12 %
1.01 %
1.01 %
1.01 %
0.61 %
0.54 %
0.00 %
0.41 %
0.06 %
1.59 %
6.13 %
7.61 %
8.18 %
8.27 %
7.55 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.80 %
17.89 %
19.49 %
18.23 %
18.57 %
20.12 %
20.51 %
18.95 %
21.85 %
24.05 %
26.82 %
25.40 %
25.45 %
27.64 %
24.54 %
24.69 %
23.94 %
24.40 %
24.43 %
Others
27.01 %
26.81 %
24.97 %
29.61 %
29.31 %
28.87 %
28.47 %
30.03 %
27.52 %
25.40 %
23.17 %
15.59 %
15.96 %
20.75 %
24.94 %
14.23 %
13.96 %
13.21 %
12.83 %
No of Share Holders
51,277
53,220
46,540
40,592
39,565
39,724
39,097
41,579
46,143
46,869
50,434
44,094
43,630
44,793
44,809
41,072
42,784
49,034
50,108

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 711.45 889.45
10 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
10 Feb 2025 708.90 689.40
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 818.60 824.85
17 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
17 Sept 2024 705.40 880.60
20 Sept 2022 DIVIDEND Dividend
₹ 1.10 /share
19 Sept 2022 410.30 393.05
22 Sept 2021 DIVIDEND Dividend
₹ 1.10 /share
20 Sept 2021 517.75 564.80

Announcements

Announcement under Regulation 30 (LODR)-Scheme of Arrangement3 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20184 days ago
Shilpa Pharma Lifesciences Limited Unit-1 ANVISA Audit From Brazil4 days ago
Announcement under Regulation 30 (LODR)-Credit Rating6 days ago
Announcement under Regulation 30 (LODR)-Scheme of Arrangement10 days ago
Closure of Trading WindowJun 26, 2025
Intimation For Participation In Investor Conference.Jun 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 26, 2025
Integrated Filing (Financial)May 26, 2025
Board Meeting Outcome Financial Results For The Quarter And Year Ended 31 March 2025May 26, 2025
Results - Financial ResultsMay 26, 2025
Board Meeting Outcome for BM OutcomeMay 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
Intimation Under Regulation 30 Of SEBI (LODR)2015May 24, 2025
Shilpa Biocare A Wholly Owned Subsidiary Of Shilpa Medicare Enters Into A Strategic Partnership With Orion Corporation (Orion) FinlandMay 23, 2025
Change Of Statutory Auditors Firm NameMay 20, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
Board Meeting Intimation for Consideration Of Audited Financial Statements (Consolidated & Standalone) For The Financial Year Ending March 31 2025 And Recommendation Of Dividend If Any For F.Y 2024-25May 19, 2025
Announcement Under Regulation 30 Of The SEBI(LODR) RegulationsMay 14, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.May 06, 2025
Revised Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 03, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 03, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 03, 2025
Celltrion Arbitral AwardApr 17, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 11, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
US Approval For Varenicline Tablets 0.5 Mg And 1 MgApr 09, 2025
Launch Of 2Nd NDA Bortezomib For Injection 3.5Mg/1.4Ml In USApr 03, 2025
Closure of Trading WindowMar 27, 2025
Execution Of Binding Term Sheet With Mabtree Biologics AGMar 17, 2025
Announcement Under Regulation 30 Of The SEBI (LODR) RegulationsMar 14, 2025
Intimation For Participation In Investor ConferenceMar 12, 2025
Disclosure under Regulation 30A of LODRMar 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 14, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Reg 2015Feb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 10, 2025
Integrated Filing (Financial)Feb 10, 2025
Unaudited Financial Results For The Quarter Ended 31St December 2024Feb 10, 2025
Board Meeting Outcome for Board Meeting OutcomeFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Board Meeting Intimation for Board Meeting Intimation To Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31 December 2024Feb 03, 2025
Shilpa Pharma Lifesciences Limited Received CEP From EDQM For API TeriflunomideJan 23, 2025
Rejection Letter From BSE For Reclassification Of Mr. Suraj Kumar Innani & Mrs.. Priya InnaniJan 21, 2025
Rejection Letter From NSE On Reclassification Of Mr. Suraj Kumar Innani & Mrs Priya InnaniJan 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Europe Approval For Tadalafil Orodisperible FilmsJan 10, 2025

Technical Indicators

RSI(14)
Neutral
54.13
ATR(14)
Less Volatile
37.03
STOCH(9,6)
Neutral
73.21
STOCH RSI(14)
Neutral
42.79
MACD(12,26)
Bearish
-7.02
ADX(14)
Weak Trend
22.37
UO(9)
Bearish
53.23
ROC(12)
Downtrend And Accelerating
-0.09
WillR(14)
Neutral
-38.64

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Small Cap Fund Direct-Growth
0.00%
-1133436
-0.87%
-0.75%
ICICI Prudential ELSS Tax Saver Direct Plan - Growth
0.00%
-1032968
-0.65%
-0.47%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.00%
-963149
-1.58%
-1.18%
Bandhan Innovation Fund Direct-Growth
0.00%
-219770
-1.31%
-1.13%
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth
0.00%
-169829
-0.65%
-0.52%
WhiteOak Capital Mid Cap Fund Direct - Growth
0.00%
-146041
-0.41%
-0.32%
WhiteOak Capital Special Opportunities Fund Direct - Growth
0.00%
-91220
-0.87%
-0.60%
WhiteOak Capital Multi Cap Fund Direct - Growth
0.00%
-73752
-0.35%
-0.28%
WhiteOak Capital Balanced Advantage Fund Direct - Growth
0.00%
-30475
-0.18%
-0.13%
ITI Pharma and Healthcare Fund Direct - Growth
0.00%
-30013
-1.22%
-0.97%
WhiteOak Capital ELSS Tax Saver Fund Direct - Growth
0.00%
-17272
-0.41%
-0.31%
Samco Multi Cap Fund Direct-Growth
0.00%
-15250
-0.37%
0.00%
WhiteOak Capital Multi Asset Allocation Fund Direct - Growth
0.00%
-10016
-0.04%
-0.03%
WhiteOak Capital Balanced Hybrid Fund Direct - Growth
0.00%
-4939
-0.24%
-0.18%
Groww Nifty Total Market Index Fund Direct - Growth
0.00%
-828
-0.02%
-0.02%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.00%
-768
-0.38%
-0.28%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.00%
-115
-0.02%
-0.02%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.00%
-110
-0.02%
-0.02%
Angel One Nifty Total Market Index Fund Direct - Growth
0.00%
-103
-0.02%
-0.02%
ICICI Prudential Multicap Fund Direct Plan-Growth
0.00%
0
0.00%
0.00%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
0
0.00%
0.00%